Development and clinical evaluation of non-viral genome specific targeted CAR T cells in relapsed/refractory B-cell non-Hodgkin lymphoma
Zhang, J.; Hu, Y.; Yang, J.; Li, W.; Tian, Y.; Wei, G.; Zhang, L.; Zhao, K.; Qi, Y.; Tan, B.; Zhang, M.; Li, Y.; Tian, Q.; Fang, C.; Wu, Y.; Li, D.; Du, B.; Liu, M.; Huang, H.
Show abstract
In recent years, chimeric antigen receptor (CAR) T cell therapy has shown great promise in treating hematological malignancies. However, using virus in manufacture of CAR T cells brings about several problems. The application of CRISPR/Cas9 genome editing technology emerges in constructing novel CAR T cells by disrupting endogenous genes. Here we successfully develop a two-in-one approach to generate non-viral genome specific targeted CAR T cells through CRISPR/Cas9. By targeting a CAR in AAVS1 safe harbor locus, we demonstrated that these CAR T cells behave comparable to those conventionally produced by lentivirus. Furthermore, PD1-knockin anti-CD19 CAR T cells show a superior ability to eradicate tumor cells with high PD-L1 expression. In the adoptive therapy for relapsed/refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL), we observed durable responses without serious adverse events and complete remission (CR) in patients treated with these PD1 knockout CAR T cells. Collectively, our results prove the safety and feasibility of non-viral genome specific integrated CAR T cells, thus providing a new potential strategy for cancer treatment using these novel CAR T cells.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Tumor Purity-Related Genes for Predicting the Prognosis and Drug Sensitivity of DLBCL Patients 94%
- NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model 92%
- Mapping of single-cell landscape of acral melanoma and analysis of molecular regulatory network of tumor microenvironment 91%
Similar papers in this journal
- Efficient and robust NK-Cell transduction with Baboon Envelope pseudotyped lentivector: a major tool for immunotherapy 94%
- HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathway 94%
- The Mechanism underlying B cell Developmental Dysfunction in Kawasaki Disease Based on Single-cell Transcriptomic Sequencing 92%
Similar papers in this journal
- A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity 92%
- A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy 91%
- Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potency 91%
Similar papers in this journal
- Analysis and Identification of Necroptosis Landscape on Therapy and Prognosis in Bladder Cancer 92%
- The Construction and Analysis of ceRNA Network and Immune Infiltration in Kidney Renal Clear Cell Carcinoma 91%
- The usage of human IGHJ genes follows a particular nonrandom selection: The recombination signal sequence affects the usage of human IGHJ genes 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.